JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM, cilt.10, sa.3, ss.127-137, 2009 (SCI-Expanded)
Introduction. The aim of this study was to investigate whether activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) contributes to the development of aldosterone-induced endothelial dysfunction and treatment with the potent PARP inhibitor 1,5-isoquinolinediol (3 mg/kg/day, i.p.) could prevent endothelial dysfunction caused by aldosterone.